Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by janddon May 23, 2004 7:03pm
248 Views
Post# 7523109

Moving targets

Moving targetsIMHO, the reason the share price is languishing is that all the forcasts for Revenue and profitability keep on shifting lower and lower. I was told back in 2001 when JV1 was signed with ARC that the deal would mean tens of millions of revenues by 2004 - now they are talking about 2007 for any meaningful revenues. Don't get me wrong, I do appreciate that the company is "moving along', but i do believe that the investment community has been misprepresented with overly optimistic forcast in the past, and this is why the share price has been languishing of late. Every time I see new revenue targets, or profitability targets, everything is being dramatically downgraded. Now we are seeing murmurs of EPS positive in 2007? One month ago, posters were touting that we would be cash-flow break even in 04 and EPS postitive in 05. I certainly hope that this is the case, or we could be heading for a $1.00 share price. Obviously the market is in a "show me, don't tell me" mood with PLI because of overly optimistic predictions in the past. The scary thing is that these current markets conditions are nasty, almost like the markets enjoying slamming the share prices of any deals that are not up to snuff. I do agree with Pierre in that most investors are missing the big picture wrt this company, and that if they are just trying to flip the shares at $3.00, they will miss out. We must also remember that on average, it takes 13 years to get a new biotech product to market, and that is only if the product does become a sucessful longshot as most new drugs and technologies never come to fruition. The challenge for the company now is to ensure that we incur meaningful revenues in fiscal '04, and that the company can attract institutional money to this play. I must admit that lately it's been a bit encouraging in that we finally have some institutioanl bids showing up in the market depth. When the stock plunged below $1.80, it appeared as though all the bids were retail as they were small and numerous. Now at least I noticed a few 10,000 lot bids consisting of only 1 bidder - that's institutioanl. Just my humble opinion Good luck to all longs JANDD
Bullboard Posts